{
  "trial_id": "NCT03514420",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, body mass index (BMI), fasting triglycerides levels, hemoglobin A1c (HbA1c), presence of type 2 diabetes mellitus, presence of hypertriglyceridemia, hepatic fat fraction (HFF), anti-diabetic therapy status, family history of familial partial lipodystrophy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Fasting Triglycerides (TG)",
          "fasting triglycerides levels"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Fasting Apolipoprotein B-48 (Apo B-48)",
        "Fasting Apolipoprotein C-III (Apo CIII)",
        "Fasting Apolipoprotein B (ApoB)",
        "Fasting Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)",
        "Fasting High Density Lipoprotein- Cholesterol (HDL-C)",
        "Fasting Apolipoprotein A-I (Apo A-1)",
        "Fasting Very low Density Lipoprotein-Cholesterol (VLDL-C)",
        "Fasting Low Density Lipoprotein Cholesterol (LDL-C)",
        "Area Under Curve (AUC) of Plasma Glucose",
        "AUC of Serum Insulin",
        "AUC of Serum C-peptide",
        "AUC of Free Fatty Acid",
        "AUC of Gastric Inhibitory Polypeptide (GIP)",
        "AUC of Glucagon-like Peptide 1 (GLP-1)",
        "AUC of Peptide Tyrosine Tyrosine (PYY)",
        "AUC of Serum Ghrelin"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "hemoglobin A1c (HbA1c)",
        "presence of type 2 diabetes mellitus",
        "presence of hypertriglyceridemia",
        "hepatic fat fraction (HFF)",
        "anti-diabetic therapy status",
        "family history of familial partial lipodystrophy."
      ]
    },
    "processed-gen-response": "Age, sex, race, body mass index (BMI), fasting triglycerides levels, hemoglobin A1c (HbA1c), presence of type 2 diabetes mellitus, presence of hypertriglyceridemia, hepatic fat fraction (HFF), anti-diabetic therapy status, family history of familial partial lipodystrophy."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, HbA1c, Fasting Triglycerides, Hepatic Fat Fraction, Duration of Diabetes, Anti-diabetic Therapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Fasting Triglycerides (TG)",
          "Fasting Triglycerides"
        ],
        [
          "HbA1c",
          "HbA1c"
        ],
        [
          "Hepatic Fat Fraction",
          "Hepatic Fat Fraction"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Fasting Apolipoprotein B-48 (Apo B-48)",
        "Fasting Apolipoprotein C-III (Apo CIII)",
        "Fasting Apolipoprotein B (ApoB)",
        "Fasting Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)",
        "Fasting High Density Lipoprotein- Cholesterol (HDL-C)",
        "Fasting Apolipoprotein A-I (Apo A-1)",
        "Fasting Very low Density Lipoprotein-Cholesterol (VLDL-C)",
        "Fasting Low Density Lipoprotein Cholesterol (LDL-C)",
        "Area Under Curve (AUC) of Plasma Glucose",
        "AUC of Serum Insulin",
        "AUC of Serum C-peptide",
        "AUC of Free Fatty Acid",
        "AUC of Gastric Inhibitory Polypeptide (GIP)",
        "AUC of Glucagon-like Peptide 1 (GLP-1)",
        "AUC of Peptide Tyrosine Tyrosine (PYY)",
        "AUC of Serum Ghrelin"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Body Mass Index",
        "Duration of Diabetes",
        "Anti-diabetic Therapy"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, HbA1c, Fasting Triglycerides, Hepatic Fat Fraction, Duration of Diabetes, Anti-diabetic Therapy"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Diabetes Diagnosis Duration, Fasting Triglycerides, HbA1c, Hepatic Fat Fraction, Body Mass Index, Waist Circumference, Family History of FPL, Genetic Mutation Status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Fasting Triglycerides (TG)",
          "Fasting Triglycerides"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Fasting Apolipoprotein B-48 (Apo B-48)",
        "Fasting Apolipoprotein C-III (Apo CIII)",
        "Fasting Apolipoprotein B (ApoB)",
        "Fasting Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)",
        "Fasting High Density Lipoprotein- Cholesterol (HDL-C)",
        "Fasting Apolipoprotein A-I (Apo A-1)",
        "Fasting Very low Density Lipoprotein-Cholesterol (VLDL-C)",
        "Fasting Low Density Lipoprotein Cholesterol (LDL-C)",
        "Area Under Curve (AUC) of Plasma Glucose",
        "AUC of Serum Insulin",
        "AUC of Serum C-peptide",
        "AUC of Free Fatty Acid",
        "AUC of Gastric Inhibitory Polypeptide (GIP)",
        "AUC of Glucagon-like Peptide 1 (GLP-1)",
        "AUC of Peptide Tyrosine Tyrosine (PYY)",
        "AUC of Serum Ghrelin"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Diabetes Diagnosis Duration",
        "HbA1c",
        "Hepatic Fat Fraction",
        "Body Mass Index",
        "Waist Circumference",
        "Family History of FPL",
        "Genetic Mutation Status"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Diabetes Diagnosis Duration, Fasting Triglycerides, HbA1c, Hepatic Fat Fraction, Body Mass Index, Waist Circumference, Family History of FPL, Genetic Mutation Status."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, weight, body mass index (BMI), waist circumference, hip circumference, systolic blood pressure, diastolic blood pressure, fasting glucose, hemoglobin A1c (HbA1c), fasting triglycerides, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, liver enzymes (aspartate aminotransferase (AST), alanine aminotransferase (ALT)), hepatic fat fraction (HFF), presence of type 2 diabetes mellitus, duration of type 2 diabetes mellitus, anti-diabetic therapy, family history of FPL.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Fasting Triglycerides (TG)",
          "fasting triglycerides"
        ],
        [
          "Fasting High Density Lipoprotein- Cholesterol (HDL-C)",
          "high-density lipoprotein (HDL) cholesterol"
        ],
        [
          "Fasting Low Density Lipoprotein Cholesterol (LDL-C)",
          "low-density lipoprotein (LDL) cholesterol"
        ],
        [
          "Hemoglobin A1c (HbA1c)",
          "hemoglobin A1c (HbA1c)"
        ],
        [
          "Hepatic Fat Fraction (HFF)",
          "hepatic fat fraction (HFF)"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Fasting Apolipoprotein B-48 (Apo B-48)",
        "Fasting Apolipoprotein C-III (Apo CIII)",
        "Fasting Apolipoprotein B (ApoB)",
        "Fasting Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)",
        "Fasting Apolipoprotein A-I (Apo A-1)",
        "Fasting Very low Density Lipoprotein-Cholesterol (VLDL-C)",
        "Area Under Curve (AUC) of Plasma Glucose",
        "AUC of Serum Insulin",
        "AUC of Serum C-peptide",
        "AUC of Free Fatty Acid",
        "AUC of Gastric Inhibitory Polypeptide (GIP)",
        "AUC of Glucagon-like Peptide 1 (GLP-1)",
        "AUC of Peptide Tyrosine Tyrosine (PYY)",
        "AUC of Serum Ghrelin"
      ],
      "remaining_candidate_features": [
        "weight",
        "body mass index (BMI)",
        "waist circumference",
        "hip circumference",
        "systolic blood pressure",
        "diastolic blood pressure",
        "fasting glucose",
        "liver enzymes (aspartate aminotransferase (AST), alanine aminotransferase (ALT))",
        "presence of type 2 diabetes mellitus",
        "duration of type 2 diabetes mellitus",
        "anti-diabetic therapy",
        "family history of FPL"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, weight, body mass index (BMI), waist circumference, hip circumference, systolic blood pressure, diastolic blood pressure, fasting glucose, hemoglobin A1c (HbA1c), fasting triglycerides, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, liver enzymes (aspartate aminotransferase (AST), alanine aminotransferase (ALT)), hepatic fat fraction (HFF), presence of type 2 diabetes mellitus, duration of type 2 diabetes mellitus, anti-diabetic therapy, family history of FPL."
  }
}